NICE highlights potential role of TheraSphere® for treatment of both operable and inoperable HCC

London, UK, 05 April 2016

BTG plc (LSE: BTG), a global specialist healthcare company, has today announced the publication of a new medtech innovation briefing (MIB) by NICE (National Institute for Health and Care Excellence) for TheraSphere® yttrium-90 glass microsphere therapy.1



TheraSphere® radioactive glass microspheres flow directly into the liver tumour via its own blood vessels and become permanently lodged in the small blood vessels of the tumour.

The MIB positions TheraSphere® as a potential treatment option for patients with both operable and inoperable HCC (hepatocellular carcinoma), as an alternative or adjunct to one of several options currently offered through the NHS, including liver resection, transplantation, local ablation, chemoembolisation and transcatheter therapies, and systemic therapies.

“With often limited alternative treatment choices available to people living with HCC, TheraSphere® represents an important new therapeutic option that is generally well-tolerated and is designed to slow and potentially stop further tumour growth,” commented Peter Pattison, BTG General Manager Interventional Oncology. “The publication of the MIB by NICE further supports TheraSphere®’s potential as a powerful, targeted and well-tolerated therapy that may lead to patients becoming eligible for other curative options.”
To access the full MIB, please visit:

About TheraSphere®

TheraSphere® 90Y glass microspheres are specifically engineered to carry far greater power than any other 90Y liver-directed cancer therapy, delivering high doses of radiation to liver tumours while sparing normal tissue. The result is a powerful, targeted and well-tolerated therapy that may lead to patients becoming eligible for curative therapies.In the EU TheraSphere® is approved for the treatment of hepatic neoplasia. For full instructions for use and important safety information, please visit
About Medtech Innovation Briefings

Medtech innovation briefings summarise the published evidence and information available for individual medical technologies. The briefings provide information to aid local decision-making by clinicians, managers and procurement professionals. Medtech innovation briefings aim to present information and critically review the strengths and weaknesses of the relevant evidence, but contain no recommendations and are not formal NICE guidance.
About BTG Interventional Medicine

BTG Interventional Medicine is part of BTG plc, a growing international specialist healthcare company. As medicine moves from major surgery to minor procedure, from the systemic to the local, no company endeavours to do more than BTG Interventional Medicine to help doctors in their quest to see more, reach further and treat smarter. Our growing portfolio of Interventional Medicine products is designed to advance the treatment of liver tumours, advanced emphysema, severe blood clots, and varicose veins. To learn more about BTG Interventional Medicine, please visit:
For further information contact:

BTG plc
Chris Sampson, Corporate Communications Director
+44 20 7575 1595; Mobile: +44 7773 251 178

Media Liaison
Jonathan Kearney
+44 208 618 2755; Mobile: +44 7725 925 841

1. NICE advice [MIB62]. TheraSphere for treating operable and inoperable hepatocellular carcinoma, Accessed March 2016.